195 related articles for article (PubMed ID: 30796905)
1. Expression and activity of the cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 is tissue and species-specific.
Dammann C; Stapelfeld C; Maser E
Chem Biol Interact; 2019 Apr; 303():57-61. PubMed ID: 30796905
[TBL] [Abstract][Full Text] [Related]
2. The cortisol-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 in skeletal muscle in the pathogenesis of the metabolic syndrome.
Loerz C; Maser E
J Steroid Biochem Mol Biol; 2017 Nov; 174():65-71. PubMed ID: 28765040
[TBL] [Abstract][Full Text] [Related]
3. 11beta-hydroxysteroid dehydrogenase type 1 and obesity.
Morton NM; Seckl JR
Front Horm Res; 2008; 36():146-164. PubMed ID: 18230901
[TBL] [Abstract][Full Text] [Related]
4. Extra-adrenal regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: physiological regulator and pharmacological target for energy partitioning.
Walker BR
Proc Nutr Soc; 2007 Feb; 66(1):1-8. PubMed ID: 17343766
[TBL] [Abstract][Full Text] [Related]
5. The role and regulation of 11β-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome.
Stimson RH; Walker BR
Horm Mol Biol Clin Investig; 2013 Sep; 15(2):37-48. PubMed ID: 25436731
[TBL] [Abstract][Full Text] [Related]
6. 11beta-Hydroxysteroid dehydrogenase Type 1 in obesity and Type 2 diabetes.
Stulnig TM; Waldhäusl W
Diabetologia; 2004 Jan; 47(1):1-11. PubMed ID: 14652720
[TBL] [Abstract][Full Text] [Related]
7. Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Iwasaki Y; Takayasu S; Nishiyama M; Tsugita M; Taguchi T; Asai M; Yoshida M; Kambayashi M; Hashimoto K
Mol Cell Endocrinol; 2008 Mar; 285(1-2):10-8. PubMed ID: 18313835
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 in antidiabetic therapy.
Wang M
Handb Exp Pharmacol; 2011; (203):127-46. PubMed ID: 21484570
[TBL] [Abstract][Full Text] [Related]
9. Regulation of 11β-HSD1 by GH/IGF-1 in key metabolic tissues may contribute to metabolic disease in GH deficient patients.
Morgan SA; Berryman DE; List EO; Lavery GG; Stewart PM; Kopchick JJ
Growth Horm IGF Res; 2022 Feb; 62():101440. PubMed ID: 34814007
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a promising therapeutic target.
Wamil M; Seckl JR
Drug Discov Today; 2007 Jul; 12(13-14):504-20. PubMed ID: 17631244
[TBL] [Abstract][Full Text] [Related]
11. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
12. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
[TBL] [Abstract][Full Text] [Related]
13. Cortisol release from adipose tissue by 11beta-hydroxysteroid dehydrogenase type 1 in humans.
Stimson RH; Andersson J; Andrew R; Redhead DN; Karpe F; Hayes PC; Olsson T; Walker BR
Diabetes; 2009 Jan; 58(1):46-53. PubMed ID: 18852329
[TBL] [Abstract][Full Text] [Related]
14. 11Beta-hydroxysteroid dehydrogenase type 1 in human disease: a novel therapeutic target.
Tomlinson JW
Minerva Endocrinol; 2005 Mar; 30(1):37-46. PubMed ID: 15877012
[TBL] [Abstract][Full Text] [Related]
15. Increased glucocorticoid receptor and 11{beta}-hydroxysteroid dehydrogenase type 1 expression in hepatocytes may contribute to the phenotype of type 2 diabetes in db/db mice.
Liu Y; Nakagawa Y; Wang Y; Sakurai R; Tripathi PV; Lutfy K; Friedman TC
Diabetes; 2005 Jan; 54(1):32-40. PubMed ID: 15616008
[TBL] [Abstract][Full Text] [Related]
16. Targeting the pre-receptor metabolism of cortisol as a novel therapy in obesity and diabetes.
Gathercole LL; Stewart PM
J Steroid Biochem Mol Biol; 2010 Oct; 122(1-3):21-7. PubMed ID: 20347978
[TBL] [Abstract][Full Text] [Related]
17. Type 2 diabetes and metabolic syndrome are associated with increased expression of 11beta-hydroxysteroid dehydrogenase 1 in obese subjects.
Alberti L; Girola A; Gilardini L; Conti A; Cattaldo S; Micheletto G; Invitti C
Int J Obes (Lond); 2007 Dec; 31(12):1826-31. PubMed ID: 17593901
[TBL] [Abstract][Full Text] [Related]
18. 11beta-Hydroxysteroid dehydrogenase type 1 inhibitors: novel agents for the treatment of metabolic syndrome and obesity-related disorders?
Anagnostis P; Katsiki N; Adamidou F; Athyros VG; Karagiannis A; Kita M; Mikhailidis DP
Metabolism; 2013 Jan; 62(1):21-33. PubMed ID: 22652056
[TBL] [Abstract][Full Text] [Related]
19. Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.
Wake DJ; Stimson RH; Tan GD; Homer NZ; Andrew R; Karpe F; Walker BR
J Clin Endocrinol Metab; 2007 May; 92(5):1848-56. PubMed ID: 17327378
[TBL] [Abstract][Full Text] [Related]
20. Altered activity of 11beta-hydroxysteroid dehydrogenase types 1 and 2 in skeletal muscle confers metabolic protection in subjects with type 2 diabetes.
Jang C; Obeyesekere VR; Dilley RJ; Krozowski Z; Inder WJ; Alford FP
J Clin Endocrinol Metab; 2007 Aug; 92(8):3314-20. PubMed ID: 17519316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]